Program
pomalidomide
Also written as “Pomalidomide”, “Pomalidomide 4 MG Oral Capsule” and “Xetrane® (Pomalidomide) 4 mg Hard Capsule”.
Its studies are mostly in Multiple Myeloma · Primary Myelofibrosis · Brain Neoplasms · Scleroderma, Systemic · Hematologic Neoplasms, led by 8 companies.
Drug pagePomalidomide: every studyMany companies study it; this page follows only the 37 they lead. All 160 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 251 open or running | phase 3since Jul 15, 2010 | Nov 7, 2003 | Jan 10, 2027phase 3 · NCT05519085 |
| Oncotherapeuticsits history only | 40 open or running | phase 2since Feb 20, 2012 | Feb 20, 2012 | none ahead |
| Amgenits history only | 20 open or running | phase 2since Nov 22, 2019 | Oct 18, 2016 | none ahead |
| Simcere Pharmaceutical Groupits history only | 20 open or running | phase 3since Sep 24, 2016 | Sep 24, 2016 | none ahead |
| Criteriumits history only | 10 open or running | phase 2since Oct 19, 2011 | Oct 19, 2011 | none ahead |
| Knight Therapeutics (USA)its history only | 10 open or running | phase 1since Jul 3, 2026 | Jul 3, 2026 | none ahead |
| Megalabsits history only | 11 open or running | phase 1since Sep 15, 2023 | Sep 15, 2023 | none ahead |
| Takedaits history only | 10 open or running | phase 4since Dec 20, 2021 | Dec 20, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 21 studies since Nov 7, 2003.
- Dec 10, 20132 phase 2 studies in Multiple MyelomaBristol-Myers Squibb · NCT02011113, NCT02045017
- Jun 18, 2014Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT02168205 · 55 enrolled · United States
- Jul 7, 20142 phase 2 studies in Multiple MyelomaOncotherapeutics · NCT02188368, NCT02206425
- Sep 24, 2016Simcere Pharmaceutical Group’s first study: phase 3 study in Multiple MyelomaNew to Simcere Pharmaceutical GroupSimcere Pharmaceutical Group · NCT02916420 · 73 enrolled · China
- Oct 18, 2016Amgen’s first study: phase 1 study in RecurrenceNew to AmgenAmgen · NCT02939183 · 61 enrolled · United States, Australia, Canada and more
- Feb 27, 2017Phase 2 study in Multiple MyelomaOncotherapeutics · NCT03104270 · 13 enrolled · United States
- Aug 18, 2017Phase 2 study in Central Nervous System NeoplasmsBristol-Myers Squibb · NCT03257631 · 53 enrolled · United States, France, Italy and more
- Dec 14, 2017Phase 1 study in Multiple MyelomaSimcere Pharmaceutical Group · NCT03424928 · 12 enrolled · China
- Aug 16, 2018Phase 3 study in Multiple MyelomaBristol-Myers Squibb · NCT03651128 · 386 enrolled · United States, Belgium, Canada and more
- Nov 22, 2019Phase 2 study in RecurrenceAmgen · NCT04191616 · 54 enrolled · United States, Denmark, Estonia and more
- Dec 20, 2021Takeda’s first study: phase 4 study in Multiple MyelomaNew to TakedaTakeda · NCT05183139
- Aug 25, 2022Phase 3 study in RecurrenceBristol-Myers Squibb · NCT05519085 · 810 planned · United States, Argentina, Australia and more
- Sep 15, 2023Megalabs’ first study: phase 1 study in Bioequivalence StudyNew to MegalabsMegalabs · NCT06058689 · 10 planned · India
- Jul 3, 2026Knight Therapeutics (USA)’s first study: phase 1 study in Pomalidomide Bioequivalence Study in Healthy VolunteersNew to Knight Therapeutics (USA)Knight Therapeutics (USA) · NCT07694011 · 34 enrolled · Chile
Ahead
- Jan 10, 2027Primary completion: phase 3 study in RecurrenceBristol-Myers Squibb · NCT05519085
TargetBeta
“CRL4(CRBN) E3 ubiquitin ligase inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lenalidomiderule | Bristol-Myers Squibb | phase 4 | 109 |
Studies
All 37 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07694011Pomalidomide Bioequivalence Study in Healthy Volunteers · Chile | 1 | Completed | Knight Therapeutics (USA) | Feb 5, 2025 | 34 |
| NCT06058689Bioequivalence Study · India | 1 | Not yet recruiting | Megalabs | Nov 15, 2024 | 10 |
| NCT05519085Recurrence · United States, Argentina, Australia and more | 3 | Recruiting | Bristol-Myers Squibb | Jan 10, 2027 | 810 |
| NCT05183139Multiple Myeloma | 4 | Withdrawn | Takeda | Dec 31, 2026 | 0 |
| NCT04191616Recurrence · United States, Denmark, Estonia and more | 2 | Completed | Amgen | Nov 30, 2022 | 54 |
| NCT03651128Multiple Myeloma · United States, Belgium, Canada and more | 3 | Completed | Bristol-Myers Squibb | Apr 13, 2026 | 386 |
| NCT03424928Multiple Myeloma · China | 1 | Completed | Simcere Pharmaceutical Group | Jan 29, 2018 | 12 |
| NCT03257631Central Nervous System Neoplasms · United States, France, Italy and more | 2 | Completed | Bristol-Myers Squibb | Sep 14, 2023 | 53 |
| NCT03104270Multiple Myeloma · United States | 2 | Terminated | Oncotherapeutics | Oct 25, 2019 | 13 |
| NCT02939183Recurrence · United States, Australia, Canada and more | 1 | Completed | Amgen | Oct 6, 2022 | 61 |
| NCT02916420Multiple Myeloma · China | 3 | UNKNOWN | Simcere Pharmaceutical Group | Jun 2018 | 73 |
| NCT02206425Multiple Myeloma · United States | 2 | Completed | Oncotherapeutics | Jan 19, 2018 | 45 |
| NCT02188368Multiple Myeloma · United States | 2 | Terminated | Oncotherapeutics | Oct 23, 2020 | 45 |
| NCT02168205Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Sep 19, 2014 | 55 |
| NCT02045017Multiple Myeloma · Austria, France, Germany and more | 2 | Completed | Bristol-Myers Squibb | Jan 27, 2017 | 81 |
| NCT02011113Multiple Myeloma · Japan | 2 | Completed | Bristol-Myers Squibb | Sep 2014 | 36 |
| NCT01986894Clinical Pharmacology, Healthy Volunteer Study · United States | 1 | Completed | Bristol-Myers Squibb | Dec 2, 2013 | 72 |
| NCT01946477Multiple Myeloma · United States, Canada, Japan and more | 2 | Completed | Bristol-Myers Squibb | Apr 30, 2025 | 186 |
| NCT01835561Liver Diseases · United States | 1 | Completed | Bristol-Myers Squibb | Aug 16, 2014 | 32 |
| NCT01734928Multiple Myeloma · United States, Austria, Canada and more | 3 | Completed | Bristol-Myers Squibb | May 9, 2022 | 559 |
| NCT01712789Multiple Myeloma · Austria, Belgium, Denmark and more | 3 | Completed | Bristol-Myers Squibb | Dec 11, 2019 | 682 |
| NCT01707407Pharmacology, Clinical · United States | 1 | Completed | Bristol-Myers Squibb | Nov 1, 2012 | 32 |
| NCT01568294Multiple Myeloma · Japan | 1 | Completed | Bristol-Myers Squibb | Jul 8, 2015 | 12 |
| NCT01559129Scleroderma, Systemic · United States, Australia, France and more | 2 | Terminated | Bristol-Myers Squibb | Nov 3, 2016 | 23 |
| NCT01541332Multiple Myeloma · United States | 2 | UNKNOWN | Oncotherapeutics | Dec 2016 | 70 |
| NCT01522547Anemia, Sickle Cell · United States | 1 | Completed | Bristol-Myers Squibb | Oct 1, 2012 | 12 |
| NCT01497093Multiple Myeloma · United States | 1 | Completed | Bristol-Myers Squibb | Jul 23, 2019 | 34 |
| NCT01474330Healthy · United States | 1 | Completed | Bristol-Myers Squibb | Oct 1, 2011 | 33 |
| NCT01464034Multiple Myeloma · United States | 2 | Terminated | Criterium | Jul 2020 | 136 |
| NCT01324947Multiple Myeloma · Australia, Belgium, Canada and more | 3 | Completed | Bristol-Myers Squibb | Jul 31, 2014 | 74 |
| NCT01311687Multiple Myeloma · United States, Australia, Belgium and more | 3 | Completed | Bristol-Myers Squibb | Mar 1, 2013 | 455 |
| NCT01178281Primary Myelofibrosis · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Jan 1, 2013 | 267 |
| NCT00833833Multiple Myeloma · United States, Canada | 2 | Completed | Bristol-Myers Squibb | Apr 2011 | 259 |
| NCT00717522Sarcoma · United States | 2 | Terminated | Bristol-Myers Squibb | Jan 1, 2009 | 7 |
| NCT00537511Carcinoma, Small Cell · United States, Canada | 2 | Terminated | Bristol-Myers Squibb | Nov 1, 2010 | 22 |
| NCT00463385Primary Myelofibrosis · United States, Austria, Italy and more | 2 | Completed | Bristol-Myers Squibb | May 1, 2009 | 88 |
| NCT00072722Prostatic Neoplasms · United States | 2 | Completed | Bristol-Myers Squibb | 36 |
How it is read
Names in the registry
- “Pomalidomide”, 41 entries
- “pomalidomide”, 4 entries
- “Pomalidomide 4 MG Oral Capsule”, 2 entries
- “Xetrane® (Pomalidomide) 4 mg Hard Capsule”, 1 entry
- “Imnovid® (Pomalidomide) 4 mg Hard Capsule”, 1 entry
Codes read as this program: CC4047.
Conditions, from the studies’ own filings
- Multiple Myeloma, 35 studies
- Primary Myelofibrosis, 2 studies
- Brain Neoplasms, 1 study
- Scleroderma, Systemic, 1 study
- Hematologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.